Shares of DXCM rose 2% to $76.02 apiece after the market closed today.
The San Diego-based continuous glucose monitor (CGM) maker reported profits of $249.1 million. That equals 64¢ per share on sales of $1.31 billion for the three months ended June 30, 2026.
Dexcom recorded a 38.5% bottom-line gain on a sales increase of 13.1%.
Adjusted to exclude one-time items, earnings per share came in at 70¢. That landed 9¢ ahead of expectations on Wall Street. Sales also topped forecasts as experts projected $1.29 billion in revenue.
Get the full story at our sister site, Drug Delivery Business News.
